10 stories mentioning IQVUpdated just now
Every FINWIRES story that references IQV, newest first.
IQVIA (IQV) shares were down over 3% in Wednesday trading after Morgan Stanley downgraded the stock to equal weight from overweight and lowered its price target to $200 from $225.Trading volume stood at more than 1 million shares, compared with a daily average of about 1.6 million.Price: $173.50, Change: $-5.67, Percent Change: -3.16%
Healthcare stocks declined Wednesday afternoon, with the NYSE Healthcare Index decreasing 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.7%.The iShares Biotechnology ETF (IBB) rose 2.2%.In corporate news, IQVIA (IQV) shares fell 3.3% after Morgan Stanley downgraded the company to equalweight from overweight and cut its price target to $200 from $225.Novo Nordisk (NVO) said it is aware of claims by cyber extortion group FulcrumSec that it stole company data and sought a $25 million payment, Reuters reported. Novo shares were up 1.8%.Moderna (MRNA) plans to invest in production sites in Germany and is interested in the plants that BioNTech (BNTX) has slated for closure, according to a Google translation of a Wednesday report from German news outlet Handelsblatt. Moderna shares jumped past 8%, and BioNTech was up 4%.
Healthcare stocks declined Wednesday afternoon, with the NYSE Healthcare Index decreasing 0.3% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.6%.The iShares Biotechnology ETF (IBB) rose 2.1%.In corporate news, IQVIA (IQV) shares fell 3.8% after Morgan Stanley downgraded the company to equalweight from overweight and cut its price target to $200 from $225.
IQVIA Holdings Inc (IQV) has an average rating of buy and mean price target of $223.28, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
IQVIA (IQV) said Thursday that a subsidiary has priced an offering of 950 million euros ($1.10 billion) of 4.625% senior notes due June 15, 2033.Proceeds will be used to refinance its debt, the company said. It expects to issue the notes on June 11.IQVIA shares were up about 3% in morning trading.Price: $187.71, Change: $+5.66, Percent Change: +3.11%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month price target to $190 from $210, a 14.8x multiple of our 2026 EPS estimate (unchanged at $12.80; 2027 estimate up $0.07 to $14.19), below IQV's one-and-three year historical forward averages of 15.6x and 18.3x, respectively. We think headwinds may persist across key life sciences end markets due to macroeconomic pressures, uncertain tariff and research funding policy, and weaker biotech spending and clinical trial activity. Positively, we think IQV benefits from its diversification compared with peers, with significant earnings coming from health care technology and analytics, as well as contract research and commercialization services. We think recent bookings figures indicate a gradually improving biopharma spending environment despite the macroeconomic headwinds, though there could be a multi-quarter lag effect for emerging biopharma funding to flow through to IQV's bookings, based on company commentary at the recent Bank of America Global Healthcare Conference.
IQVIA (IQV) posted better-than-expected Q1 revenue and EPS, reinforcing contract research organization recovery thesis, RBC Capital Markets said in a note Tuesday."We believe the setup is positive," the report said, pointing toaccelerated organic growth, AI tailwind, and mid-to-high single digits growth in forward-looking demand indicators.The note pointed to improving growth in Commercial, driven in part by strength in Patient Solutions and analytics & consulting.The report said it reflects large pharma deploying capital towards late-stage assets with the highest probability of success.AI-enabled offerings are also gaining traction, with clients selecting IQVIA to build AI-ready data foundations and record pipelines in analytics & consulting, the report added.RBC kept its outperform rating and $221 price target.Price: $177.38, Change: $+0.96, Percent Change: +0.54%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our 12-month price target at $210, based on 16.4x our 2026 EPS estimate, above IQV's one-year historical forward average of 15.6x but a discount to its five-year historical forward average of 20.6x. This is justified by recent headwinds for key life sciences end markets due to macroeconomic pressures, uncertain tariff and research funding policy, and weaker biotech spending and clinical trial activity, in our view. We raise our 2026 EPS estimate to $12.80 from $12.70 and lower our 2027 estimate by $0.07 to $14.12. Adjusted for IQV's new segment reporting, R&DS saw net new bookings of $2.5B in Q1 2026 (up 3.6% Y/Y), generating a book-to-bill ratio of 1.04x, somewhat weaker than recent trends. Management attributed this to an unfavorable clinical trial mix rather than an indicator of weakening demand. Per Q1 earnings commentary, the company has deployed 192 AI agents across 64 use cases, with 19 of the top-20 pharmaceutical companies having adopted some of these offerings.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:IQVIA reported Q1 2026 revenue of $4,151M (+8.4% Y/Y), led by robust Commercial Solutions growth (+11.6% Y/Y) and steady R&D Solutions performance (+6.2% Y/Y). Adjusted EPS of $2.90 (+7.4% Y/Y) exceeded guidance and beat consensus by $0.08. R&D Solutions bookings were encouraging, in our view, with net new bookings of $2.5B generating a book-to-bill ratio of 1.04x amid what management described as a stabilizing biopharmaceutical market. IQV raised 2026 adjusted EPS guidance to $12.65-$12.95 (up $0.10 at the midpoint) while reaffirming revenue and EBITDA guidance. The contracted backlog of $34.2B supports revenue visibility, with $8.9B expected to convert over the next twelve months (+7.6% Y/Y), though EBITDA margin declined to 22.5% from 23.1%. We view mid-to-high single digit growth in forward-looking demand indicators as suggesting continued client momentum, while the company maintained flexibility with $552M in share repurchases and 15% FCF growth to $491M.
IQVIA Holdings Inc (IQV) has an average rating of buy and mean price target of $228.20, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $157.53, Change: $-0.84, Percent Change: -0.53%
